# NCT03918252 (NCT03918252)

> Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

No report yet. It can be ordered.

- Drugs tested: nivolumab; nivolumab plus ipilimumab
- Indication: resectable malignant pleural mesothelioma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03918252
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Conditions: Mesothelioma
- Interventions: Nivolumab Injection; Ipilimumab Injection
- Enrollment: 30
- Primary outcome: Safety Profile of neoadjuvant nivolumab +/- ipilimumab in patients with resectable malignant pleural mesothelioma (MPM) with grade III/IV adverse events defined by CTCAE v5.0
- Primary outcome: Feasibility of neoadjuvant nivolumab +/- ipilimumab in patients with resectable MPM who complete of neoadjuvant treatment and proceed to surgery

## Indexed commentary on NCT03918252 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03918252